<DOC>
	<DOC>NCT02532374</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD, i.e., subjective effects) profiles, and the safety and tolerability of the nicotine-containing aerosol delivered by Platform 3 Liquid (P3L) system at three different nicotine levels in smoking healthy subjects in Relation to NicoretteÂ®.</brief_summary>
	<brief_title>Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<criteria>Subject is Caucasian Smoking, healthy subject as judged by the Investigator Subject smoked at least 10 commercially available nonmenthol conventional/combustible cigarettes (CCs) per day for the last 4 weeks Subject does not plan to quit smoking in the next 3 months As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) Subject has donated or been in receipt of whole blood or blood products within 3 months prior to Admission Visit Female subject is pregnant or breast feeding Female subject does not agree to use an acceptable method of effective contraception Female subject uses estrogencontaining hormonal contraception or hormone replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>nicotine absorption</keyword>
	<keyword>nicotine containing product</keyword>
	<keyword>conventional cigarette</keyword>
	<keyword>Nicorette</keyword>
	<keyword>combustible cigarette</keyword>
	<keyword>nicotine delivery system</keyword>
</DOC>